mardi 10 décembre 2019

Onco Actu du 10 décembre 2019


2.6 ETIOLOGIE - ENVIRONNEMENT



Austrian leader blocks ban on weedkiller glyphosate, citing technicality [Reuters]











France to ban dozens of glyphosate weedkillers amid health risk debate [Reuters]











4.9 DÉP., DIAG. & PRONO. - SEIN



New test predicts chance of living more than a year on targeted breast cancer treatment [Institute of Cancer Research]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Researchers Create a Potential Therapy for Deadly Breast Cancer That Has Few Treatment Options [Mount Sinai]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



PAK4 Inhibition Increases Anti-PD-1 Response in Mouse Models Prompting Phase I Trial [Genome Web]











UCLA study shows inhibition of gene helps overcome resistance to immunotherapy [UCLA]











Cancer immunotherapy gets assist from micro-scale engineering [Fred Hutch]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Bristol-Myers is making a bee-line to the FDA with positive liso-cel data — but is it too late in the CAR-T game? [EndPoints]











5.12.6 IMMUNOTHÉRAPIES - AMM



FDA Approves Atezolizumab With Nab-paclitaxel and Carboplatin for Metastatic Non-squamous NSCLC Without EGFR/ALK Aberrations [ESMO]











5.2 PHARMA



Sanofi CEO Hudson lays out new R&D focus -- chopping diabetes, cardio and slashing $2B-plus costs in surgical dissection [EndPoints]











Sanofi ends research in diabetes, narrows units to spur profit [Reuters]











5.2.1 PHARMA - PARTENARIATS



Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay [Adaptive Biotechnologies]











5.2.2 PHARMA - FUSIONS & ACQUISITIONS



Merck's ArQule buy showcases pharma appetite for targeted cancer drugs [Biopharma Dive]










Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego’s Synthorx [Xconomy]










Sanofi CEO offers clues of tomorrow's vision reveal with cancer biotech buy [Fierce Pharma]











Merck inks $2.7B ArQule deal, teeing up cancer race with Lilly [Fierce Biotech]











Sanofi buys Synthorx for $2.5B in prelude to Hudson's strategy rollout [Biopharma Dive]











Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule [Xconomy]











New Sanofi CEO Hudson adds next-gen cancer drug tech to the R&D quest, buying Synthorx for $2.5B [EndPoints]











Merck and Sanofi buy smaller cancer drug firms at big premiums, fueling investor excitement [STAT]











Merck to Acquire ArQule, Advancing Leadership in Oncology [Merck]











Here’s why Merck is paying $2.7B today to grab ArQule and its next-gen BTK drug, lining up Eli Lilly rivalry [EndPoints]











5.8.3 ASH - DIVERS



ASH Study: Germline Testing Identifies Cancer Risk Mutations, VUS in Older AML Patients [Genome Web]











Gimme shelter: CRISPR hides healthy cells from leukemia drug [Fred Hutch]











5.8.4 ASH - CAR-T



As CAR-T presses ahead in multiple myeloma, alternative approaches gain supporters [Biopharma Dive]










Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting [Novartis]










Bridging Therapy Not Recommended for All CAR T Patients [Moffitt Cancer Center]











5.8.5 ASH - MYÉLOME MULTIPLE



ASH: J&J's anti-BCMA CAR-T clears multiple myeloma in 69% of patients in phase 1 [Fierce Biotech]











ASH: Amgen's BiTE stalls multiple myeloma relapse in mice in combo with BMS' Revlimid [Fierce Biotech]











ASH: J&J's Darzalex cuts death risk by 40% in new myeloma patients [Fierce Pharma]











DARZALEX® (Daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant [Johnson & Johnson]











Bluebird bio, Bristol-Myers' multiple myeloma therapy shows promise in early study [Reuters]











Game on: Regeneron's BCMA bispecific makes clinical data debut, kicking off multiple myeloma matchup with Bristol-Myers [EndPoints]











bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition [BMS]











5.8.6 ASH - LEUCÉMIES



ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting [ArQule]











Combination therapy more effective than chemotherapy alone for many newly diagnosed leukemia patients [MD Anderson Cancer Center]











Leukemia Combo Toxic for Old, Frail Patients [SWOG]











5.8.7 ASH - LYMPHOMES



Treatment with PD-1 inhibitor prior to stem cell transplant is safe, effective for patients with classic Hodgkin lymphoma, study finds [Dana-Farber Cancer Institute]











Kite Presents Positive Results From Pivotal ZUMA-2 Trial in Relapsed or Refractory Mantle Cell Lymphoma [Kite]











Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting [Takeda]











CAR T-cell therapy effective for relapsed mantle cell lymphoma patients [MD Anderson Cancer Center]











6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES



Spinning a negative acupuncture study: Same as it ever was [Science-Based Medicine]